Cycle Pharmaceuticals Launches Sajazir for HAE


The company has also launched a website for patients affected by hereditary angioedema, a rare genetic disorder.

Cycle Pharmaceuticals has launched Sajazir (icatibant) injection, a new treatment option for patients affected by hereditary angioedema (HAE). The therapy is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.

Hereditary angioedema is a rare genetic potentially life-threatening disorder that results in recurring attacks of edema in various parts of the body, including the abdomen, extremities (hands/feet), genitals, face, and throat. It affects about 1 in 50,000 people. Type I is the most common, accounting for 85% of cases.

The company has also launched a newly created website for patients, called Cycle Vita, which is a support hub for those with rare diseases (

John Reid

John Reid

“Cycle Vita is an essential part of our core mission to better support patients with HAE and their families. We will appropriately guide patients through every stage of their journey by streamlining the enrollment and finance process and provide ongoing treatment support in addition to the expertise of the patient’s health care team.” John Reid, director of patient hub services, said in a statement.

Sajazir is supplied in a prefilled syringe. Patients may self-administer the therapy subcutaneously upon recognition of symptoms of a HAE attack after training under the guidance of a health care professional or a registered nurse from Cycle Vita.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.